CTI BioPharma blood cancer drug meets study goal

March 9, 2015 4:50 PM

12
0

(Reuters) - CTI BioPharma Corp's experimental blood cancer drug achieved the main goal of a late-stage study, but at least two analysts said the pill would not directly compete with Incyte Corp's treatment.

The company's shares shot up 10.9 percent in early morning trading, but were up only 4 percent at midday on the Nasdaq.